叶娜

发布者：金雪明发布时间：2018-12-04浏览次数：10626

 

  


职务职称：博士，副教授，硕士生导师

联系邮箱：yena@suda.edu.cn

联系地址：苏州市工业园区仁爱路199号药学院云轩楼1225


个人简介：


  1. 学习与工作经历

2016.9–至今：苏州大学药学院，副教授，独立PI

2013.6–2016.8：美国德州大学医学分部，博士后

2008.09-2013.06：中国科学院上海药物研究所，药物化学，理学博士

2004.09-2008.07：沈阳药科大学，国家基础药学理科基地班，理学学士


  1. 研究方向

1）靶向神经精神性重大疾病的药物研发

2）抗肿瘤药物的设计与合成


  1. 主要学术科研成果


长期从事药物化学及化学生物学研究，通过运用有机合成方法，结合现代药物设计新理念和新方法，进行中枢神经系统疾病和恶性肿瘤新药研究。至今在J Med Chem,Adv Sci,Acta Pharmaceutica Sinica B,Eur J Med Chem,Bioorg Chem,ACS Chem Neurosci, Acta Pharmacol Sin和Org Biomol Chem等药物化学与有机化学期刊上发表SCI论文近60篇，其中第一及通讯作者30余篇，高被引论文1篇。共申报国内外发明专利10余项、其中7项中国专利已授权，2项新药专利已转让。并编写“十二五”国家重点图书《新药研发案例研究：明星药物如何从实验室走向市场》第十章。设计开发的靶向聚腺苷二磷酸核糖聚合酶PARP抑制剂SOMCL-9112已申报化学药品1.1类抗肿瘤新药，即希明哌瑞及其片剂，获得了卫生部优先评审品种推荐及中国药监局颁发的新药临床实验批件，目前正在临床试验Ib/IIa中。

目前主持在研国家自然科学基金面上项目2项、已完成国家和江苏省自然科学基金青年项目等5项，作为研究骨干（排名第二）参与在研国家重点研发项目1项。独立指导本科生获得校级“莙政基金”项目（本科生以第一作者发表了SCI论文等2篇）和江苏省大学生创新性试验计划各1项。


代表性论文如下(*通讯作者；#并列第一作者)：

1）Zhao X, Zhong C, Zhu R, Gong R, Liu B, He L, Tian S, Jin J, Jiang T, Chen JL, Wan X, Liu W, Jiang S, Deng P, Cheng Y,*Ye N.* Structure−Activity Relationship Studies of Substituted 2 Phenyl-1,2,4-triazine-3,5(2H,4H) dione Analogues: Development of Potent eEF2K Degraders against Triple-Negative Breast Cancer.J. Med. Chem.2024, 67(17), 15837-15861. (Q1, IF 6.8)

2）Tang W, Ma Z, Li B, Yu Z, Zhao X, Yang H, Hu J, Tian S, Gu L, Chen J, Zou X, Wang Q, Chen F, Li G, Zheng C, Gao S, Liu W, Li Y, Zheng W, Wang M,Ye, N,* Zhen X.* Discovery and proof-of-concept study of a novel highly selective sigma-1 receptor agonist for antipsychotic drug development.Acta Pharmaceutica Sinica B, 2025, March20,accepted. (Q1, IF 14.9)

3）Wan X, Gong R, Zhao X, Li Y, Shan T, Zhong C, Zhu R, Chen Z, Jiang S, He L, Cao S, Tian S, Yang J,Ye N,* Yi W,* Cheng Y.* Identification of a novel substrate for eEF2K and the AURKA-SOX8 as the related pathway in TNBC. Adv. Sci.2025, 2412985,DOI: 10.1002/advs.202412985. (Q1, IF 14.3)

4）Ye N,* Wang Q, Li Y, Zhen XC.* Current Emerging Therapeutic Targets and Clinical Investigational Agents for Schizophrenia: Challenges and Opportunities,Med. Res. Rev.2025,45, 755-787. (Q1, IF 10.9)

5）Zhong C, Zhu R, Jiang T, Tian S, Zhao X, Wan X, Jiang S, Chen Z, Gong R, He L, Yang J,Ye N,* Cheng Y.* Design and Characterization of a Novel eEF2K Degrader with Potent Therapeutic Efficacy Against Triple-Negative Breast Cancer.Adv. Sci.2024,11(5), e2305035. (Q1, IF 14.3)

6）Zhang Y, Yu Z,Ye N,* Zhen X.* Macrophage migration inhibitory factor (MIF) in CNS diseases: Functional regulation and potential therapeutic indication. Fundamental Research,2024,4(6), 1375-1388. (Q2，IF 5.7)

7）Zhu R, Jiang G, Tang W, Zhao X, Chen F, Zhang X,Ye N.* Aporphines: A privileged scaffold in CNS drug discovery.Eur. J. Med. Chem.2023,256, 115414. (Q1, IF 6.0)

8）Ying Z#;Ye N#; Ma Q, Chen F, Li N, Zhen X. Targeted to neuronal organelles for CNS drug development.Adv. Drug Deliv. Rev.2023,200, 115025. (Q1, IF 15.2)

9）Mao Q, Zhang B, Tian S, Qin W, Chen J, Huang XP, Xin Y, Yang H, Zhen XC,* Shui W,*Ye N.* Structural optimizations and bioevaluation of N-H aporphine analogues as Gq-biased and selective serotonin 5-HT2C receptor agonists.Bioorg. Chem.2022,123, 105795. (Q1, IF 5.1)

10）Kuang Y#;Ye N#; Kyani A, Ljungman M, Paulsen M, Chen H, Zhou M, Wild C, Chen H, Zhou J, Neamati N.*Induction of Genes Implicated in Stress Response and Autophagy by a Novel Quinolin-8-yl-nicotinamide QN523 in Pancreatic Cancer.J. Med. Chem.2022,65, 6133-6156. (Q1, IF 7.3)

11）Wang P#, van der Hoeven D#,Ye N,# Chen H, Liu Z, Ma X, Montufar-Solis D; Rehl KM, Cho, KJ, Thapa S, Chen W, van der Hoeven R, Frost JA, Hancock JF, Zhou J. Scaffold repurposing of fendiline: Identification of potent KRAS plasma membrane localization inhibitors.Eur. J. Med. Chem.2021,217, 113381. (Q1, IF 7.088)

12）Ye N;* Qin W, Tian S, Xu Q, Wold EA, Zhou J, Zhen XC. Small Molecules Selectively Targeting Sigma-1 Receptor for the Treatment of Neurological Diseases.J. Med. Chem.2020,63, 15187-15217. (Q1, IF 7.446)

13）Mao Q, Zhang B, Li W, Tian S, Shui W,Ye N.* Identification of Novel 1-O-Substituted Aporphine Analogues as Potent 5-HT2C Receptor Agonists.ACS Chem. Neurosci.2020,11, 549−559.(Q2, IF 4.418)

14）Mao Q, Qin W, Zhang A,Ye N.* Overview of recent advances on dopaminergic strategies for Parkinson’s disease.Acta Pharmacol. Sin.2020,41, 471-482.(Q1, IF 6.15)

15）Xu Q, Li B, Ma Y, Sun F, Gao Y,Ye N.* K2S2O8-HFIP Synergistic Promotedpara-selective sp3 C-H Bond Diarylation of Glycine Esters.Org. Biomol. Chem.,2020,18, 666-670.(Q3, IF 3.876)

16）Ye, N.* Drug Discovery by Targeting Mutant KRAS.Curr. Top. Med. Chem.2019,19, 2079-2080. (Editoral; Guest editor)

17）Li B, Mao Q, Zhou J, Liu F,Ye N.* HFIP-Promoted Michael Reactions: Direct para-Selective C-H Activation of Anilines with Maleimides.Org. Biomol. Chem.2019,17, 2242-2246.(Q3, IF 3.890)

18）Yuan B#,Ye N#, Song SS, Wang YT, Song Z, Chen HD, Chen CH, Huan XJ, Wang YQ, Su Y, Shen YY, Sun YM, Yang XY, Chen Y, Guo SY, Gan Y, Gao ZW, Chen XY, Ding J, He JX, Zhang A, Miao ZH. Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials.Cancer Lett.2017,386, 47-56. (Q1, IF 6.491)

19）Ye N,# Zhu Y, # Liu Z, Mei FC, Chen H, Wang P, Cheng X, Zhou J. Identification of novel 2-(benzo[d]isoxazol-3-yl)-2-oxo-N-phenylacetohydrazonoyl cyanide analoguesas potent EPAC antagonists.Eur. J. Med. Chem.2017,134, 62-71. (Q1, IF 6.514)

20）Ye N, Chen H, Wold EA, Shi PY, Zhou J. Therapeutic Potential of Spirooxindoles as Antiviral Agents.ACS Infect. Dis.2016,2, 382-392. (Q2, IF 5.084高被引论文)





课题组热忱欢迎有志从事药物化学相关研究的本科生、硕士研究生和博士研究生到课题组学习工作。有疑问请随时邮件联系yena@suda.edu.cn。